Has Cyaandi Dove received payments from drug or device companies?

Yes. Drug and device makers reported $50,971 in general payments to Cyaandi Dove across 63 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Cyaandi Dove did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Cyaandi Dove come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Cyaandi Dove

Podiatrist · Grand Ronde, ORNPI 1750490553

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $32,894 of the $50,971 with a category attached, or 64.5%. ETS Wound Care LLC accounts for 77.5% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $43,176, more than ten times the $80 reported in 2019. Among podiatrist clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$50,971in general payments, 2019–2025

Across 63 payments — averaging $809.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

ETS Wound Care LLC$40K
Advanced Oxygen Therapy Inc.$5K
Kerecis Limited$4K
Averitas Pharma Inc.$350
Solventum Corporation$267
Integra Lifesciences Corporation$194
plus $840 from 8 others

$174,257in research payments, 2019–2025

Across 10 payments — averaging $17,426 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Biotissue Holdings Inc.$128K
Smith+Nephew$19K
Kerecis Limited$15K
Acera Surgical, Inc.$12K

What the payments were for

Consulting fees$32,89465%
Speaking & faculty fees$1,6003%
Travel & lodging$12,09724%
Food & beverage$4,2638%
Education$1170%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
ETS Wound Care LLC	37	$39,506
Advanced Oxygen Therapy Inc.	2	$5,376
Kerecis Limited	4	$4,437
Averitas Pharma Inc.	4	$350
Solventum Corporation	5	$267
Integra Lifesciences Corporation	2	$194
Molnlycke Health Care US, LLC	1	$172
Johnson & Johnson	1	$147
Organogenesis Inc.	1	$125
Paratek Pharmaceuticals, Inc.	1	$124
Globus Medical	1	$121
Cardiovascular Systems Inc.	1	$80
Smith+Nephew	2	$53
Urgo Medical North America, LLC	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

MIRRAGEN ADVANCED WOUND MATRIX$38,907
Kerecis Omega3 Marigen$10,544
Kerecis SurgiClose$6,400
Topical oxygen chamber for extremities$5,376
Kerecis Omega3 SurgiClose$3,282
Kerecis GraftGuide$1,600
Kerecis Omega3 GraftGuide$360
INTEGRA$335
Qutenza$270
MOTOBAND$147
Affinity$125
NUZYRA$124
Senza$121
INTEGRA DERMAL REGENERATION TEMPLATE$112
PRIMATRIX$112

How this compares

$50,971 in reported general payments places this provider in the 95th percentile of 74 podiatrist providers in Oregon.

See all podiatrist providers in Oregon →

Medicare billing

Part B allowed, 2024

$17,039

Medicare patients

Services billed

175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Naftifine Hcl	13	$2,732
Ketoconazole	76	$2,606
CiclopiroxCiclopirox Olamine	14	$280

Paid to pharmacies, not to this prescriber.

Other podiatrist in Grand Ronde

Rick McClureMedford$133K
Stephen SchroederTigard$28K
Colin MizuoHillsboro$18K
Melinda NicholesPortland$15K
Amanda KameryEugene$9K
Peter PhamBeaverton$8K
Liang-Chieh KoEugene$7K
Kyle VillaruzGrants Pass$7K
Lyndon JohansenPortland$6K
Nathan WindsorHillsboro$6K

See the full list for Oregon →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →